Drug Research
Schreiner MediPharm Equips Cap-Lock Security Label with RFID Technology
Schreiner MediPharm, a Germany-based global provider of innovative functional label solutions for the healthcare industry, has enhanced its tamper-evident specialty label, Cap-Lock, with a special RFID inlay. Developed to help hospitals expand digitization initiatives, the label-and-cap security concept for...
News
Catalent to Acquire Cell Therapy Manufacturing Facility from Bone Therapeutics
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that it had signed an agreement with Bone Therapeutics to acquire its cell therapy...
News
CStone signs pact to out-license ex-Greater China rights for immune checkpoint inhibitors, sugemalimab & CS1003 to EQRx
CStone Pharmaceuticals announced an agreement to out-license ex-Greater China rights for two key late-stage immuno-oncology assets, sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1), to EQRx, a biopharmaceutical company with an innovative business model that will allow these drugs to be competitively...
News
BioInvent licenses anti-Fc?RllB antibody BI-1206 to CASI Pharmaceuticals for Greater China region
BioInvent International AB, a biotechnology company focused on the discovery and development of first-in-class immune-modulatory antibodies for cancer immunotherapy, and CASI Pharmaceuticals, Inc, a U.S. biopharmaceutical company with an established clinical development and commercial infrastructure in China, announced they...
News
Bayer acquires Asklepios BioPharmaceutical to broaden innovation base in cell and gene therapy
Acquisition fuels Bayer’s cell and gene therapy platform with potential to bring urgently needed treatments to patients across multiple disease areas with high unmet need / AskBio's industry leading AAV-based gene therapy platform already yielding commercial and clinical stage...
News
Lilly to Supply 300,000 Vials of Neutralizing Antibody Bamlanivimab in an Effort to Fight COVID-19
Eli Lilly and Company announced an initial agreement with the U.S. government to supply 300,000 vials of bamlanivimab (LY-CoV555) 700 mg, an investigational neutralizing antibody, for $375 million. The U.S. government will accept the vials of bamlanivimab if it...
News
Integration of Movilitas.Cloud and NiceLabel Simplifies Serialized Label Printing for Highly Regulated Industries
Movilitas today announced the integration of its Movilitas.Cloud with NiceLabel’s cloud-based label printing solution to simplify serialized label printing for highly regulated industries. With 50% of all label printers globally shipped with NiceLabel technology and over 16 million labels...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.